This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Cinnarizine with dimenhydrinate oral


Tablets containing cinnarizine and dimenhydrinate

Drugs List

  • ARLEVERT tablets
  • cinnarizine 20mg and dimenhydrinate 40mg tablets
  • Therapeutic Indications


    Meniere's disease



    One tablet three times a day.


    One tablet three times a day.


    Children under 18 years
    Epileptic disorder
    Narrow angle glaucoma
    Raised intracranial pressure
    Renal impairment - creatinine clearance below 25 ml/minute
    Severe hepatic impairment
    Urinary retention secondary to benign prostatic hyperplasia

    Precautions and Warnings

    Predisposition to glaucoma
    Benign prostatic hyperplasia
    Hepatic impairment
    Mild renal impairment
    Parkinson's disease
    Pyloroduodenal obstruction
    Raised intra-ocular pressure
    Severe cardiac disorder

    May mask ototoxicity caused by ototoxic drugs e.g. salicylates
    Advise ability to drive/operate machinery may be affected by side effects
    Review therapy after 4 weeks
    Treatment may prevent a positive reaction to dermal reactivity indicators
    Advise patient to avoid alcohol during treatment
    Advise patient to take after food to reduce gastro-intestinal disturbances

    Pregnancy and Lactation


    Cinnarizine and dimenhydrinate tablets are contraindicated in pregnancy.

    The manufacture recommends against the use of cinnarizine and dimenhydrinate tablets in pregnancy.Cinnarizine and dimenhydrinate both have low teratogenic effect and have been used in pregnancy for many years. It is not known if cinnarizine crosses the placenta. The molecular weight and elimination half life suggest that exposure of the embryo and foetus should be expected. Dimenhydrinate may have an oxytoxic effect and may shorten labour.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Cinnarizine and dimenhydrinate tablets are contraindicated in breastfeeding.

    Dimenhydrinate and cinnarizine are excreted in low quantities in human breast milk.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abdominal pain
    Aplastic anaemia
    Chest tightness
    Cholestatic jaundice
    Dazed feeling
    Dry mouth
    Excitement (paradoxical)
    Extrapyramidal effects
    Glaucoma (closed angle)
    Hypersensitivity reactions
    Lichen planus
    Lupus erythematosus-like syndrome
    Skin reactions
    Urinary hesitancy
    Visual disturbances
    Weight gain


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: March 2014

    Reference Sources

    Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.

    Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.

    Joint Formulary Committee. British National Formulary. 66th ed. London: BMJ Group and Pharmaceutical Press; 2013. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press [Accessed on February 12, 2014].

    Summary of Product Characteristics: Arlevert 20 mg/40mg tablets. Hennig Arzneimittel GmbH Co. KG. Revised January 2013

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.